Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
An experimental drug has shown a striking effectiveness in prolonging the lives of people with heart failure and could replace what has been the bedrock treatment for more than 20 years, researchers said Saturday.
The drug, which is being developed by the Swiss company Novartis, reduced both the risk of dying from cardiovascular causes and the risk of being hospitalized for worsening heart failure by about 20 percent in a large clinical trial.
"I think that when physicians see these data, they will find it compelling, and what we will see is a paradigm shift," said Dr. Milton Packer, a professor of clinical sciences at the University of Texas Southwestern Medical Center in Dallas and one of the two principal investigators in the study.
http://www.houstonchronicle.com/new...ws-big-promise-for-heart-patients-5724400.php
The drug, which is being developed by the Swiss company Novartis, reduced both the risk of dying from cardiovascular causes and the risk of being hospitalized for worsening heart failure by about 20 percent in a large clinical trial.
"I think that when physicians see these data, they will find it compelling, and what we will see is a paradigm shift," said Dr. Milton Packer, a professor of clinical sciences at the University of Texas Southwestern Medical Center in Dallas and one of the two principal investigators in the study.
http://www.houstonchronicle.com/new...ws-big-promise-for-heart-patients-5724400.php